Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.52 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.52 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3329456 | 0.90 | CA12 (0.44) | LMNACA12CA1CA2CA9 | |
| SCHEMBL3330052 | 0.85 | CA12 (0.45) | CA12CA1CA2CA9MAPT | |
| SCHEMBL3328613 | 0.80 | CCNA2 (0.44) | CA12CA1CA2CA9 | |
| SCHEMBL3329633 | 0.73 | RHOC (0.39) | ALDH1A1MAPT | |
| SCHEMBL6710157 | 0.72 | ALDH1A1 (0.40) | LMNARORCALDH1A1HTTMAPT | |
| SCHEMBL3327827 | 0.72 | KCNH2 (0.44) | LMNAALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL3581872 | 0.72 | CNR1 (0.41) | LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3583939 | 0.71 | KDM4E (0.49) | LMNAALDH1A1HTTMAPTHSD17B10 | |
| SCHEMBL17766791 | 0.71 | IDO1 (0.63) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1308602 | 0.70 | L3MBTL1 (0.52) | LMNARORCALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137381-A1 | ACETAMIDE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | US | claimed |
| US-20100137381-A1 | ACETAMIDE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-06-03 | — | — | US | disclosed |
| EP-2152677-A1 | ACETAMIDE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008135447-A1 | ACETAMIDE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137381-A1 | ACETAMIDE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ1, KCNN2 | LMNA 3641/4885KCNJ6 51/4885KCNJ5 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.